IRVINE, Calif. and HERSTAL, Belgium, Jan. 28, 2016 -- MDxHealth SA (Euronext: MDXH.BR), announced today that it will be participating at the following key conferences during the first half of 2016:
-
Bank Degroof Petercam Healthcare CEO Seminar on 03 February, Hotel Bloom Brussels, Belgium
-
LSP Biocapital Europe on 09 March, Sofitel Legend Amsterdam, The Grand, The Netherlands
-
European Association of Urology Annual Congress, 11-15 March, Messe Munich International, Germany
-
KBC Securities Benelux Biotech & Healthcare Conference on 22 March, KBC Securities Brussels, Belgium
-
American Urology Association Meeting, 06-10 May, Convention Center of San Diego, California
- FlandersBio Knowledge for Growth on 26 May, ICC Ghent, Belgium
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic and epigenetic (methylation) molecular technologies and assist physicians with the diagnosis of urological cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
|
For more information: Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 [email protected] |
|
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR) Consilium Strategic Communications UK: +44 20 3709 5701 [email protected] |
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
To access the PDF version, click here http://hugin.info/137314/R/1981850/726160.pdf
HUG#1981850


Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 



